Because cases of non-congenital lens opacities have been reported in pediatric patients treated with CFTR modulators, it is recommended that pediatric patients who are treated with these agents undergo baseline and follow-up ophthalmological examinations [35,36,37]. This evidence concerns the gene CFTR and cataract.